ArticleBiology methods & protocols2026
DRAQ7 overcomes the complications associated with autofluorescence of doxorubicin during flow cytometric analyses.
Article in Biology methods & protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin (DOX) is a widely used chemotherapeutic agent that induces apoptosis through DNA intercalation, topoisomerase II inhibition, and oxidative stress. However, its cardiotoxicity is a significant concern. Flow cytometry, particularly with Annexin V/propidium iodide (PI) or Annexin V/7AAD assays, is commonly used to assess DOX-induced cell death. A challenge arises from DOX's intrinsic fluorescence, which interferes with accurate detection. To address this, we successfully used DRAQ7, a far-red dye, in HeLa and other cancer cell lines. As our study demonstrates DRAQ7 eliminates auto-fluorescence interference, this approach offers precise differentiation of apoptotic cells and improving experimental and therapeutic reliability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.